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21.4 ± 3.3 h. Six (12%) patients presented eight ventricular 
tachyarrhythmias during WCD period: five episodes of VF, 
two sustained ventricular tachycardia (VT) and one non-
sustained VT occurred.
Conclusion This multicentre study underpins the elevated 
risk for ventricular tachyarrhythmias in patients with newly 
diagnosed PPCM and reduced LVEF. A WCD should be 
considered for 3–6 months in these patients to prevent sud-
den cardiac death from ventricular tachyarrhythmias.
Keywords Peripartum cardiomyopathy · Sudden 
cardiac death · Ventricular tachyarrhythmia · Wearable 
cardioverter/defibrillator
Abstract 
Introduction Peripartum cardiomyopathy (PPCM) is a 
rare cardiomyopathy characterized by an acute reduction 
in left ventricular ejection fraction (LVEF). Sudden deaths 
during the course of PPCM are reported to be elevated, the 
underlying mechanisms remains unknown. The aim of the 
present multi-centre study was to evaluate the arrhythmia 
burden in a multi-centre approach in patients with PPCM 
using a wearable cardioverter/defibrillator (WCD).
Methods and results Forty-nine patients from 16 Ger-
man centres with newly diagnosed PPCM and LVEF ≤35% 
receiving a WCD were included in this retrospective anal-
ysis. Mean follow-up was 15 ± 10  months. At diagnosis, 
mean age was 33 ± 5  years, parity was 2.1 ± 1.6, LVEF 
was 21 ± 7%, NYHA functional class was 3.4 ± 0.7. Mean 
wear time was 120 ± 106 days, mean wear time per day was 
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Introduction
Peripartum cardiomyopathy (PPCM) is a rare cardio-
myopathy with acute, possibly severe and sometimes life-
threatening course [1, 2]. Even though the rate of sudden 
deaths in the course of PPCM seems to be elevated [3], the 
underlying mechanisms are yet to be elucidated. Data on 
arrhythmia in PPCM is patchy [4]. One known mechanism 
of sudden death in left ventricular dysfunction is ventricu-
lar arrhythmia. In a small single-centre study, we recently 
reported that a relevant proportion of patients with newly 
diagnosed PPCM experiences life-threatening ventricu-
lar arrhythmias in the first months after diagnosis, thereby 
making arrhythmias the most plausible mechanism for sud-
den cardiac death (SCD) in this population [5]. Sudden 
arrhythmic death, however, may potentially be avoided by 
defibrillator therapy. Since the majority of patients with 
PPCM recover in LV dysfunction within 3–6  months, 
implantation of a permanent cardioverter/defibrillator for a 
transient time of risk would be an overtreatment.
The wearable cardioverter/defibrillator (WCD) repre-
sents a safe, non-invasive and effective option to prevent 
sudden arrhythmic death in patients with a transient or 
unknown risk [6]. Additionally, the WCD enables continu-
ous rhythm monitoring especially for asymptomatic tach-
yarrhythmias. Therefore, the aim of the present multicentre 
study was to evaluate the arrhythmia burden in a multicen-
tre approach in patients with PPCM and reduced LVEF 
using the WCD.
Methods
In this national multi-centre study, patient data from 16 
German primary, secondary and tertiary centres were 
pooled for retrospective analysis. The study was conducted 
in accordance with the Declaration of Helsinki. All patients 
with newly diagnosed PPCM and reduced left ventricular 
ejection fraction (LVEF) ≤35% receiving a WCD were 
included from each participating centre. Date of diagno-
sis was between 10/2011 and 03/2016. Data of 7 patients 
from Hannover Medical School have already been pre-
sented previously [5]. Diagnosis of PPCM was established 
according to the ESC definition [1]. All patients showed 
an LVEF ≤35% at diagnosis. Patients received standard 
heart failure therapy according to current guidelines and 
were followed-up according to the treating physician’s dis-
cretion. All patients received a WCD  (LifeVest®, ZOLL, 
Pittsburgh, PA, USA) after diagnosis. WCD data (arrhyth-
mia events, wearing compliance, technical problems) were 
registered with the remote monitoring system provided by 
the manufacturer (LifeVest  Network®, ZOLL, Pittsburgh, 
PA, USA). Arrhythmias were classified by two experienced 
electrophysiologists (DD, CV) to assess the type of arrhyth-
mia, the mode of onset and the mechanism of termination.
Statistics
Continuous variables are presented as mean ± standard 
deviation and 95% confidence interval (CI). Categorical 
variables are presented as number of patients and percent-
ages. Statistical analysis was performed using IBM SPSS 
Statistics version 24 (IBM, Armonk, NY, USA). Differ-
ences between groups were analysed using Student’s t test 
for continuous variables and Mann–Whitney U test for cat-
egorical variables, respectively. A p value <0.05 was con-
sidered statistically significant.
Results
Forty-nine patients from 16 German centres were identi-
fied and fulfilled inclusion criteria. Date of diagnosis was 
between 10/2011 and 03/2016. Baseline characteristics are 
shown in Table 1A. No patient died during follow-up.
WCD data
All patients received a WCD and were instructed to wear it 
continuously until re-evaluation. Cumulative wear time of 
WCD for all patients adds up to more than 15 patient-years 
(5838 days). WCD data are shown in Table 1B. One patient 
refused to continue wearing the WCD  and  further medi-
cal attendance after 10 days. However, she is known to be 
alive 12 months after diagnosis. Furthermore, another five 
patients showed a reduced wearing compliance of <20 h/
day. One of them was unable to wear the WCD continu-
ously because of a progressive dermatomycosis adjacent to 
the lateral shock electrode.
Brady- and tachyarrhythmias
No supraventricular arrhythmias or asystoles were detected. 
Eight ventricular arrhythmias were detected by the WCD in 
six patients during WCD wearing period. Five episodes of 
ventricular fibrillation (VF), two sustained ventricular tach-
ycardia (VT) and one non-sustained ventricular tachycar-
dia (nsVT) occurred (see Figs.  1, 2). Ventricular arrhyth-
mias occurred between 30 and 160 days after diagnosis of 
PPCM (Fig.  3). Detailed information on arrhythmia epi-
sodes are shown in Table 2. One patient with 2 VF episodes 
within 1 h refused ICD implantation for a prolonged time 
and continued WCD wearing for more than 1 year, finally 
accepting ICD implantation. Another patient showed stable 
monomorphic VT (TCL 290  ms) after 160  days (Fig.  2), 
starting with a first episode terminating spontaneously after 
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2  min but starting again after a few minutes. The patient 
was able to call the ambulance and VT was hemodynami-
cally tolerated during transport. The duration of sustained 
VT documented is more than 20  min. The patient with-
held any WCD therapy by pushing the response buttons 
and WCD was taken off in the emergency room where car-
dioversion was performed. In this cohort, no inappropriate 
therapies were delivered by the WCD.
Comparison of baseline parameters did not show any 
significant differences between patients with vs. without 
ventricular arrhythmias (Table 3).
Follow-up
One patient was lost to follow-up after 10  days. For 
the remaining 48 patients, mean follow-up was 15 ± 10 
(12–17) months. Thirty-nine (80%) patients showed recov-
ery of LVEF beyond 45%. Mean LVEF at last follow-up 
was 48.5 ± 10.9 (45–52)  %. NYHA functional class at 
last follow-up was 1.4 ± 0.6 (1.2–1.6). All patients with 
ventricular arrhythmic events finally received an ICD or 
CRT-D. The patient with the nsVT had a primary preven-
tive ICD indication due to persistently reduced LVEF of 
25%. Overall, at last follow-up, an ICD was implanted in 
seven patients and a CRT-D was implanted in four patients, 
respectively. After termination of the WCD wearing period, 
no further VT/VF episodes or syncopes were reported dur-
ing long-term follow-up. One patient received ablation of 
monomorphic premature ventricular contractions. No ven-
tricular tachyarrhythmia was documented in ICD/CRT-D 
recipients.
Discussion
The present study was conducted to analyse the burden of 
ventricular arrhythmias in a larger population with newly 
diagnosed PPCM using the WCD. This is the largest study 
on patients with PPCM and severely reduced LVEF with 
continuous rhythm monitoring during the early phase of the 
disease.
The main finding of the study is that in a national, 
multi-centre approach, we found a relevant amount of 
VF episodes and potentially life-threatening ventricular 
arrhythmias in patients with newly diagnosed PPCM and 
reduced LVEF. During the WCD wearing period of about 
Table 1  Baseline 
characteristics (A) and wearable 
cardioverter/defibrillator 
(WCD) data (B) for all patients 
(n = 49)
LVEF left ventricular ejection fraction, NYHA New York Heart Association functional class, ARB angioten-




 Age (years) 33 ± 5 (95% CI 32–35)
 Timing of diagnosis (days from delivery) 57 ± 57 (95% CI 41–73)
 Parity (n) 2.1 ± 1.6 (95% CI 1.7–2.6)
 LVEF at diagnosis (%) 21 ± 7 (95% CI 19–23)
 NYHA functional class 3.4 ± 0.7 (95% CI 3.2–3.6)
 NTproBNP (ng/L) (n = 37) 4965 ± 7328 (95% CI 2604–7327)
 Betablocker
  n, % 98%)
  % from target dose 43 ± 26 (95% CI 36–50)
 ACE inhibitor/ARB
  n, % 98%)
  % from target dose 40 ± 24 (95% CI 33–46)
 MRA
  n, % 88%)
  % from target dose 56 ± 44 (95% CI 44–68)
 Bromocriptine
  n, % 43 (88%)
B. WCD data
 Wear time (days) 120 ± 106 (95% CI 90–150)
 Wear time per day (h/day) 21.4 ± 3.3 (95% CI 20.5–22.2)
 Patients with VT/VF episodes (n, %) 6 (12%)
 Inappropriate WCD shocks (n) 0
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Fig. 1  One episode of ventricular fibrillation (VF) in patient #11 with appropriate therapy by the wearable cardioverter/defibrillator. Note the 
short episodes of non-sustained ventricular tachycardia before onset of VF
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3–6  months, we observed episodes of VF, sustained VT 
and nsVT in 12% of patients confirming an increased risk 
of arrhythmias in early PPCM.
Knowledge of aetiology, risk-factors and management of 
PPCM has strongly evolved in recent years [7]. However, 
the literature on the incidence of ventricular arrhythmias 
and sudden death in the course of PPCM is sparse. This 
refers to the rareness and also a presumed underdiagno-
sis of the disease. Thus, only case reports, case series and 
retrospective registries are available for estimation of the 
Fig. 2  This figure depicts the onset of one episode of sustained monomorphic ventricular tachycardia (VT) in patient #42. Tachycardia cycle 
length was 290 ms (205bpm). The VT was hemodynamically tolerated for more than 20 min until cardioversion in the emergency room
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incidence of ventricular tachyarrhythmias and sudden death 
in PPCM [4]. Diao et al. described 1 out of 19 patients with 
PPCM presenting 4 nsVT during a 24 h Holter ECG [8]. 
In a case series from Pakistan, Laghari reported 3 (6.6%) 
patients with a VT at presentation [9]. A retrospective 
analysis of patients with PPCM wearing a WCD did not 
show any ventricular arrhythmias during WCD wearing 
[10]. However, specificity of the diagnosis of PPCM, espe-
cially in this study is disputable, since the diagnosis was 
only based on referral for cardiomyopathy coupled with a 
reference on the WCD-prescription to a current or recent 
pregnancy, thereby not representing the diagnostic cri-
teria of the ESC. In a single-centre study, we have previ-
ously reported that there is a relevant risk for VF in the first 
months after diagnosis of PPCM with severely reduced left 
ventricular function [5]. However, a potential bias cannot 
be excluded as our centre is a tertiary centre with special 
focus on PPCM.
Thus, there was a need to put our previous results into 
perspective including patients with PPCM from Germany 
wearing a WCD after diagnosis. The present study is the 
first multicentre study representing patients with newly 
diagnosed PPCM treated in primary, secondary and tertiary 
medical centres. In all patients, the diagnosis of PPCM was 
based on the recommendation of the ESC [1].
In this multicentre study, we could underpin the high 
incidence of malignant ventricular tachyarrhythmias in 
12% of the patients early after diagnosis of PPCM with a 
severely reduced LVEF. Thus, our multicentre data suggest 
a potential benefit from a temporary protection from SCD 
in this cardiomyopathy.
Patients with PPCM and severely reduced LVEF 
typically recover in the majority of cases [11]. Never-
theless, severely reduced LVEF remains at high risk for 
SCD. Our data shows that patients with PPCM are fac-
ing a relevant risk for life-threatening arrhythmias in the 
Table 2  Episodes of ventricular tachyarrhythmia documented by the wearable cardioverter/defibrillator (WCD). TCL tachycardia cycle length
Episode # Patient # Event Time from 
diagnosis to 
event
Mechanism of induction Termination Time from detection to 
shock
1 7 Ventricular fibrillation 40 days Spontaneous Appropriate WCD shock 34 s
2 11 Ventricular fibrillation 68 days Short-long-short 
sequence
Appropriate WCD shock 34 s
3 Ventricular fibrillation 68 days Short-long-short 
sequence
Appropriate WCD shock 29 s
4 15 Ventricular fibrillation 83 days Short-long-short 
sequence
Appropriate WCD shock 116 s
5 18 Ventricular fibrillation 124 days Short-long-short 
sequence
Appropriate WCD shock 50 s
6 23 1 non-sustained ven-
tricular tachycardia 
(TCL 380 ms)
85 days Spontaneous Spontaneous after 17 s 17 s (no shock)
7 42 Sustained ventricular 
tachycardia (TCL 
290 ms)
165 days Spontaneous Spontaneous after 2 min >2 min (no shock)
8 Sustained ventricular 
tachycardia (TCL 
290 ms)
165 days Spontaneous WCD therapy withheld 
by patient, cardiover-
sion in emergency 
room, VT duration 
>20 min
>20 min (cardioversion)
Table 3  Comparison of 
baseline parameters between 
patients with (n = 43) and 
without (n = 6) ventricular 
arrhythmias did not show 
significant differences
Patients without ventricular 
arrhythmias (n = 43)
Patients with ventricular 
arrhythmias (n = 6)
Age (years) 34 ± 5 (95% CI 32–35) 31 ± 2 (95% CI 29–33)
Timing of diagnosis (days from delivery) 56 ± 57 (95% CI 39–73) 69 ± 54 (95% CI 26–113)
Parity (n) 2.1 ± 1.7 (95% CI 1.6–2.6) 2.3 ± 0.9 (95% CI 1.6–3.1)
LVEF at diagnosis (%) 21 ± 7 (95% CI 19–23) 19 ± 8 (95% CI 13–25)
NYHA functional class at diagnosis 3.4 ± 0.8 (95% CI 3.2–3.6) 3.2 ± 0.7 (95% CI 2.6–3.7)
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first months after diagnosis. The WCD has shown to be 
effective in preventing sudden cardiac death in several 
other cardiomyopathies [12], especially post myocardial 
infarction and in non-ischemic cardiomyopathy [13–15]. 
In the special setting of ICD removal due to infection, a 
WCD-guided strategy has been shown to be cost-effec-
tive [16]. An equivalent analysis for patients with PPCM 
having worn a WCD may support the decision to provide 
the WCD to these patients. Our data do not allow a cost-
effectiveness analysis. However, saving young mother’s 
lives may be difficult to count up and costs of WCD- pre-
scription may be justifiable.
In the early phase after diagnosis of a reduced LVEF, 
the WCD can offer protected time for optimization of 
heart failure medication and reverse left ventricular 
remodelling. A structured approach for prolonged but, 
however, secured optimization of heart failure therapies 
has been recently published [17].
The value of the WCD in our particular patients diag-
nosed with PPCM and reduced systolic LV function is 
the prevention of sudden arrhythmic death but without 
any long-term risks of an implantable device, especially 
considering the high rate of recovery. Since the events 
in our study occurred after 30–160 days after diagnosis, 
we suggest a wearing time of the WCD for 3–6 months 
independently of the LVEF as VF was observed in one 
patient even after recovery of LVEF to 45%.
Limitations
Peripartum cardiomyopathy remains a rare disease and 
structured studies on arrhythmia burden have not been 
performed to date. The present study is a retrospective 
study and is therefore, prone for all known limitations 
of this study design. It may reflect a selection bias since 
only patients having worn a WCD were included. Only 
patients with LVEF ≤35% were prescribed a WCD in 
the participating centres, therefore, our highly selected 
cohort shows a much lower mean LVEF than other 
cohorts reported from Germany [11] or elsewhere [3]. 
As wear time in our cohort was excellent, WCD wear-
ing serves as a long-term ECG monitor offering the 
chance to document symptomatic and asymptomatic 
ventricular tachyarrhythmias. Larger studies on world-
wide incidence, management and outcome in PPCM are 
actually under way [18, 19]. These studies should aim to 
identify the mode of death and the arrhythmia burden, 
to improve prevention from sudden arrhythmic death in 
these patients.
Conclusion
Patients with newly diagnosed PPCM and reduced LVEF 
show an elevated risk for ventricular tachyarrhythmias. A 
WCD should be considered for 3–6 months in all of these 
patients to prevent sudden cardiac death due to ventricular 
tachyarrhythmias.
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